Medicine and Dentistry
Fecal Microbiota Transplantation
100%
Infection
66%
Clostridium Difficile Infection
39%
Prospective Cohort Study
33%
Vancomycin
20%
Antibiotics
20%
Patient with Inflammatory Bowel Disease
18%
Hemicolectomy
16%
Colon Cancer
16%
Bile Acid Malabsorption
16%
Thiamine
16%
Drug Megadose
16%
Maintenance Therapy
16%
Loose Feces
16%
Small Intestinal Bacterial Overgrowth
16%
Fidaxomicin
16%
Ustekinumab
16%
Placebo
16%
Inflammatory Bowel Disease
16%
Metabolite
16%
Feces
11%
Adverse Event
7%
Fibroblast Growth Factor 19
7%
Riboflavin
6%
Colonoscopy
5%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
68%
Feces microflora
66%
Inflammatory Bowel Disease
36%
Ustekinumab
33%
Clostridium Difficile Infection
22%
Cohort Study
19%
Antibiotic Agent
18%
Nonalcoholic Fatty Liver
16%
Vedolizumab
16%
Prospective Cohort Study
16%
Fidaxomicin
16%
Thiamine
16%
Vancomycin
16%
Riboflavin
6%
Keyphrases
Fecal Microbiota Transplantation
33%
Scoping Review
16%
Fidaxomicin
16%
Method Validation
16%
Real-world Effectiveness
16%
Clostridium Difficile Infection
16%
Clinical Resolution
10%
Clostridium Difficile-associated Diarrhea
5%
Confidence Interval
5%
